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The two main histological types of esophageal cancer are adeno-
carcinoma and squamous cell carcinoma, each being etiologically 
distinct (1). Incidence rates of esophageal adenocarcinoma have 
sharply increased during the past 30 years in many countries, espe-
cially among populations residing in the developed countries of 
the Western world, such as Denmark, Finland, Norway, Sweden, 
Switzerland, United Kingdom and the United States (2–5). 
Incidence rates of esophagogastric junctional adenocarcinoma, 
adenocarcinomas which traverse or are wholly within the esophageal–
gastric junction, may also have increased during the same period 
(6), although the validity of such statistics and the precise relation 
between esophageal adenocarcinoma and esophagogastric junc-
tional adenocarcinoma have been debated (7,8).
Several population-based case–control studies were initiated in 
the 1990s and the 2000s to investigate the etiology of esophageal 
adenocarcinoma and esophagogastric junctional adenocarcinoma 
(9–18). Some large-scale cohort studies have also studied the risk 
factors for these two cancers (19,20). These studies have thus far 
consistently identified male sex, white race, cigarette smoking, 
gastroesophageal acid reflux, and obesity as risk factors for 
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tric junctional adenocarcinoma (12); the United Kingdom Study of 
Oesophageal Adenocarcinoma in Women (13); the Los Angeles 
County Multi-ethnic Case–control Study (14); the Nebraska 
Health Study II (15); the Nova Scotia Barrett Esophagus Study 
(16); the Factors Influencing the Barrett’s Adenocarcinoma 
Relationship Study (17); and the nationwide Australian Cancer 
Study (esophageal cancer component) (18). The two cohort 
studies were the National Institutes of Health–AARP (NIH-
AARP) Diet and Health Study with follow-up through 2003 (19); 
and the Kaiser-Permanente Multiphasic Health Checkup Study 
with follow-up to 2006 (20). For the NIH-AARP Study, all eligible 
case patients and a random sample of control subjects, four times 
as many as the case patients, were selected for the analysis. For the 
Kaiser-Permanente Multiphasic Health Checkup Study, all case 
patients and a random sample of control subjects, eight times as 
many as the case patients, were selected.
From these 12 studies, the BEACON database was able to provide 
4214 case patients (2138 esophageal adenocarcinoma and 2076 
esophagogastric junctional adenocarcinoma) and 13 750 control 
subjects eligible for the pooled analysis. We excluded participants 
who had smoked pipe tobacco (731 case patients and 1613 control 
subjects), cigars (406 case patients and 1139 control subjects), or 
used snuff (124 case patients and 224 control subjects), if the study 
provided such data, because comparing cigarette smokers with 
those who do not use other forms of tobacco provides a more 
esophageal adenocarcinoma and esophagogastric junctional ade-
nocarcinoma (9–22).
Although most of the published studies have shown smoking to 
be associated with increased risks of esophageal adenocarcinoma 
and esophagogastric junctional adenocarcinoma (9–14,16–19), the 
small size of these individual studies has limited the precision of 
resulting estimates of association. In addition, it is unknown 
whether a clear dose–response relationship between smoking and 
esophageal adenocarcinoma and esophagogastric junctional ade-
nocarcinoma exists; an important consideration if causality is to be 
inferred. It is also not known whether the associations between 
smoking and esophageal adenocarcinoma and esophagogastric 
junctional adenocarcinoma are similar in men and women—a key 
etiologic question—given the large sex disparities in cancer inci-
dence of these sites (23). It is also not clear whether the association 
with smoking is similar between esophageal adenocarcinoma and 
esophagogastric junctional adenocarcinoma. Last, it will be useful 
to know whether cigarette smoking cessation, and over what pe-
riod of time, leads to reduced risks of esophageal adenocarcinoma 
and esophagogastric junctional adenocarcinoma because this is 
likely to have utility for public health.
In 2005, a consortium entitled Barrett’s Esophagus and 
Esophageal Adenocarcinoma Consortium (BEACON) was formed 
by investigators of population-based case–control and cohort 
studies on esophageal adenocarcinoma and its precursor lesion, 
Barrett’s esophagus (9–20). The BEACON was supported by the 
US National Cancer Institute with the objective of facilitating 
well-powered combined investigations of risk factors of esophageal 
adenocarcinoma and Barrett’s esophagus and helping the develop-
ment of new studies of etiology, prevention, and survival. In this 
study, we used a two-stage analytic approach to calculate study-
specific estimates using the data available from 12 studies in 
BEACON and then combining these estimates using meta-
analytic models. Ten of the 12 studies used a population-based 
case–control design to investigate potential risk factors of adeno-
carcinoma of the esophagus. The two prospective cohort studies 
have been used for assessments of different diseases and contrib-
uted esophageal adenocarcinoma and esophagogastric junctional 
adenocarcinoma case patients and unaffected randomly selected 
control subjects to the BEACON consortium. The primary ob-
jectives were to evaluate the association between cigarette 
smoking and esophageal adenocarcinoma and esophagogastric 
junctional adenocarcinoma, test for a dose–response association 
with pack-years, analyze whether the association differed between 
men and women, and assess whether smoking cessation resulted in 
a reduced risk of these cancers.
Subjects and Methods
Study Population
The case patients and control subjects were identified in June 2008 
from the 12 studies participating in BEACON. The 12 studies 
included 10 population-based case–control studies and two cohort 
studies (Table 1). The 10 case–control studies were as follows: the 
Population Health Study (9); the Larynx, Esophagus, and Oral 
Cavity Study (10); the United States Multi-Center Study (11); a 
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accurate estimate of the effect of cigarette smoking. Because of the 
relatively small number of non-white non-Hispanic case patients 
in BEACON studies (50 black, 112 Hispanic, and 71 other race or 
ethnic groups), we restricted our analysis to white non-Hispanic 
study participants. After these exclusions, 2990 case patients (1540 
esophageal adenocarcinoma and 1450 esophagogastric junctional 
adenocarcinoma) and 9453 control subjects remained in the 
analysis.
The characteristics of the participating studies are listed in 
Table 1. Data acquisition and data pooling for each study was 
approved by the institutional review board or research ethics 
committee of the institute(s) sponsoring the study.
Study Variables
The variables used in this analysis were case or control status 
(esophageal adenocarcinoma, esophagogastric junctional adeno-
carcinoma, or control), cigarette smoking status (ever vs never), 
total smoking exposure (pack-years; 0, <15, 15–29, 30–44, ≥45), 
smoking intensity (<1, 1, and >1 pack per day; based on the most 
common number of one pack per day), age of smoking initiation 
(<17, ≥17 years), cigarette type (filtered only, nonfiltered only, or 
both), duration of smoking cessation (current smoker, <10, ≥10 
years), age, sex, education, body mass index (BMI; weight divided 
by square of height [kg/m2]), gastroesophageal reflux status (yes vs 
no), and study center (for multicenter studies only). Nine of the 12 
studies included in this analysis defined ever–cigarette smoking 
status as having smoked more than or equal to 100 cigarettes in 
their entire lifetime. The remaining three studies, two of which 
were of case–control design, used regular or daily smoking for a 
minimum continuous time period of 3, 6, or 12 months (13,14,19). 
Smoking duration was calculated as the age cigarette smoking was 
initiated to the age of quitting (for former smokers) or to the cur-
rent age (for current smokers); current age was defined as age at 
diagnosis for case patients, age at interview for control subjects, 
and age at baseline for participants of cohort studies. For analysis, 
age at smoking initiation and duration of smoking cessation were 
dichotomized based on the median values among control subjects 
who smoked.
The NIH-AARP Diet and Health Study did not ascertain the 
age of smoking initiation from case patients and control subjects. 
The median age at smoking initiation was 17 years in a subset 
of the NIH-AARP Diet and Health Study cohort (40%) that 
Table 1. Characteristics of the BEACON studies included in the pooled analysis*
Study, first author, year 
(reference) Design Location











Population Health Study,  
 Brown, 1994 (9)
Case–control United States 1986–1989 445 37 74 111
Larynx, Esophagus, and Oral Cavity  
 Study, Vaughan, 1995 (10)
Case–control United States 1983–1990 502 82 110 192
United States Multi-Center Study,  
 Gammon, 1997 (11)
Case–control United States 1993–1995 470 217 194 411
Swedish Esophageal Cancer  
 Study, Lagergren, 2000 (12)
Case–control Sweden 1995–1997 461 89 113 202
United Kingdom Study of  
 Oesophageal Adenocarcinoma  
 in Women, Cheng, 2000 (13)
Case–control United Kingdom 1993–1996 61 60 — 60
Los Angeles County Multi-ethnic  
 Case–control Study, Wu,  
 2001 (14)
Case–control United States 1992–1997 636 128 155 283
Nebraska Health Study II, Chen,  
 2002 (15)
Case–control United States 1988–1993 396 87 31 118
Nova Scotia Barrett Esophagus  
 Study, Veugelers, 2006 (16)
Case–control Canada 2001–2003 86 42 — 42
Factors Influencing the Barrett’s  
 Adenocarcinoma Relationship  
 Study, Anderson, 2007 (17)
Case–control Ireland 2002–2004 220 98 66 164
Australian Cancer Study  
 (esophageal cancer component),  
 Whiteman, 2008 (18)
Case–control Australia 2001–2005 1512 359 419 778
National Institutes of Health– 
 AARP Diet and Health Study,  
 Freedman, 2007 (19)
Cohort United States 1995–1996 2478 249 198 447
Kaiser-Permanente Multiphasic  
 Health Checkup Study, Corley,  
 2008 (20)
Cohort United States 1964–1973 2186 92 90 182
* The number (n) of control subjects and case patients (EA, EGJA, and AA) included in the analyses of cigarette smoking and adenocarcinomas of the esophagus 
and esophagogastric junction. Analyses were conducted using a two-stage strategy; first, study-specific odds ratios were estimated, followed by a second step 
of pooling the study-specific odds ratios in a meta-analysis to estimate summary odds ratios of association. Analyses excluded those who smoked pipe, cigar, or 
used snuff, and non-white subjects. — = the study did not have EGJA case patients; AA = all adenocarcinoma (EA and EGJA); BEACON = Barrett’s Esophagus 
and Esophageal Adenocarcinoma Consortium; EA = esophageal adenocarcinoma; EGJA = esophagogastric junctional adenocarcinoma.
† The control subjects for the cohort studies constituted a random selection of those without cancer at the last date of follow-up.
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completed a follow-up questionnaire. Therefore, we estimated 
smoking duration by subtracting 17 years from current age (for 
current smokers) or age of last cigarette smoking (for former 
smokers). Smoking intensity in both cohort studies and smoking 
duration in the Kaiser-Permanente Multiphasic Health Checkup 
Study were ascertained in categories rather than asking for the 
precise number of years. Therefore, we recoded each category to 
the median of that category as determined using the distribution of 
years from all remaining studies.
Questionnaire data were ascertained at or near the time of can-
cer diagnosis for case patients and at age of recruitment for control 
subjects for the 10 population-based case–control studies in 
BEACON. For the two cohort studies, questionnaire data were 
ascertained at recruitment into the study (baseline). The median 
time between baseline and cancer diagnosis was 3.9 years for 
NIH-AARP Diet and Health Study (19) and 24.1 years for Kaiser 
Permanente Multiphasic Health Checkup Study (20). Data on 
gastroesophageal reflux were missing in seven studies (9,10,13,15, 
16,19,20), age at smoking initiation in two studies (19, 20), ciga-
rette type in seven studies (13,15–20), and duration of smoking 
cessation in one study (20). All other variables were available for 
all studies. A different methodology and/or categorization for the 
variable education were used in each study and, therefore, were 
study specific.
Statistical Analysis
We used a two-step analytic approach. First, we used multivariable 
logistic regression models to estimate study-specific odds ratios 
(ORs) and 95% confidence intervals (CIs) of the association 
between exposure and outcome in each study. The odds ratio 
approximates the relative risk when the outcome of interest is rare. 
Second, the study-specific odds ratios were pooled using random-
effects meta-analysis to generate summary odds ratios (24). A study 
was excluded from an analysis if it was unable to generate a stable 
odds ratio. The main exposures of interest were cigarette smoking 
status (ever, never) and total smoking exposure (in units of 
pack-years). The main outcomes of interest were esophageal 
adenocarcinoma, esophagogastric junctional adenocarcinoma, and 
a combination of both (ie, all adenocarcinoma). Continuous vari-
ables were categorized in all analyses for ease of interpretation and 
to reduce the effect of any outliers. The only exception to this was 
the use of pack-years of smoking as a continuous variable when 
estimating a P value for trend (Ptrend). For the analyses of the pri-
mary objectives, two multivariable logistic regression models were 
used—a minimally adjusted model that included the covariates age 
(categorical: <50, 50–59, 60–69, ≥70) and sex, and a fully adjusted 
model that included the covariates such as age (categorical: <50, 
50–59, 60–69, ≥70), sex, BMI (categorical: <25, 25–29.9, ≥30), 
education (study specific), gastroesophageal reflux (where available), 
and study center (where appropriate). More extensive adjustment 
in the second model made the summary odds ratios slightly, 
but not materially, attenuated. We present only the results from 
the fully adjusted model. The same methodology was used for sex-
specific analyses.
We also examined the association between smoking intensity, 
age of smoking initiation, cigarette type, and duration of smoking 
cessation with cancer risk, adjusting for pack-years of smoking, 
age, sex, BMI, education, gastroesophageal reflux, and study cen-
ter. Last, we conducted analyses stratified by BMI and interaction 
models of BMI and pack-years of cigarette smoking to assess 
whether BMI modified the relationship between smoking and 
cancer risk.
To pool the study-specific odds ratios, we used both fixed-
effects and random-effects meta-analytic models. The summary 
odds ratios from the two approaches were similar; thus, we only 
show the results from the random-effects models. Such models 
provide more conservative summary odds ratios when heteroge-
neity is present, although uncommon exceptions do exist (25). The 
I2 statistic (26) was used to estimate the percentage of total varia-
tion across studies due to heterogeneity. An I2 statistic of 0% 
indicates no observed heterogeneity that cannot be attributed to 
chance, whereas larger values indicate increasing heterogeneity. 
We also conducted a sensitivity analysis that omits each study in 
turn, reestimating the association each time to determine if any 
single study dominates the summary odds ratio. All analyses were 
performed using STATA software, version 10.1 (StataCorp LP, 
College Station, TX). All statistical tests were two-sided. P values 
less than .05 were considered to be statistically significant.
Results
The study design, study location, and numbers of case patients and 
control subjects for each of the 12 participating BEACON studies 
are described in Table 1. A total of 2990 all adenocarcinoma sub-
jects, which included 1540 esophageal adenocarcinoma subjects 
from 12 studies and 1450 esophagogastric junctional adenocarci-
noma subjects from 10 studies, were available for the analysis. A 
total of 9453 population-based control subjects were available for 
comparison. In the pooled analyses of ever–cigarette smoking, 
we observed statistically significant associations with esophageal 
adenocarcinoma (summary OR = 1.96, 95% CI = 1.64 to 2.34), 
esophagogastric junctional adenocarcinoma (summary OR = 2.18, 
95% CI = 1.84 to 2.58), and all adenocarcinoma (summary OR = 
2.08, 95% CI = 1.83 to 2.37) (Table 2). The I2 values from the 
random-effects meta-analyses of ever–cigarette smoking indicated 
low levels of heterogeneity for esophageal adenocarcinoma (I2 = 
24%), esophagogastric junctional adenocarcinoma (I2 = 21%), and 
all adenocarcinoma (I2 = 21%). The low levels of heterogeneity are 
visually apparent from the forest plots shown in Figure 1, A–C, 
each of which displays the study-specific odds ratios as well as the 
summary odds ratio for a cancer group in relation to the exposure 
ever–cigarette smoking.
We next evaluated if there was a dose–response association 
between cigarette smoking and esophageal adenocarcinoma, 
esophagogastric junctional adenocarcinoma, and all adenocarci-
noma (Table 2 and Supplementary Figure 1, A–C, available 
online). Analyses of total cigarette smoking exposure (pack-years) 
showed a highly statistically significant dose–response association 
(Ptrend < .001) and consistency in estimates of risk for each category of 
pack-year exposure across outcome groups. For all adenocarci-
noma, compared with never–cigarette smokers, statistically signif-
icant associations were noted in less than 15 pack-years (summary 
OR = 1.30, 95% CI = 1.07 to 1.58), 15–29 pack-years (summary 
OR = 2.19, 95% CI = 1.86 to 2.58), 30–44 pack-years (adjusted 
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adjusting for total dose (pack-years of cigarette smoking) (Table 3). 
The combined analytic group of all adenocarcinoma offered the high-
est statistical power as it contains all of the case patients. Cigarette 
smoking intensity, age of smoking initiation, and cigarette type were 
not associated with risk of all adenocarcinoma after adjustment for 
total dose. Compared with current cigarette smokers, smoking cessa-
tion of less than 10 years (summary OR = 0.82, 95% CI = 0.60 to 1.13) 
and greater than or equal to 10 years (summary OR = 0.71, 95% CI = 
0.56 to 0.89) showed reduced risk of all adenocarcinoma. However, 
when compared with never–cigarette smokers, greater than or equal 
to 10 years of smoking cessation was still associated with an increased 
risk of all adenocarcinoma (summary OR = 1.72, 95% CI = 1.38 to 
2.15, I2 = 55%) (data not shown in Table 3).
Discussion
The results of this pooled analysis demonstrate a consistent 
association between cigarette smoking and risk of esophageal 
OR = 2.38, 95% CI = 1.98 to 2.86), and greater than or equal to 45 
pack-years (adjusted OR = 2.73, 95% CI = 2.27 to 3.29).
For sex-specific analyses, 2457 men and 533 women with all 
adenocarcinoma (1275 men and 265 women with esophageal 
adenocarcinoma; 1182 men and 268 women with esophagogastric 
junctional adenocarcinoma) were included. We observed a statisti-
cally significant association between ever–cigarette smoking and 
esophageal adenocarcinoma for men (summary OR = 2.10, 95% 
CI = 1.71 to 2.59) and women (summary OR = 1.74, 95% CI = 1.21 
to 2.51), esophagogastric junctional adenocarcinoma for men 
(summary OR = 2.23, 95% CI = 1.88 to 2.63) and women (sum-
mary OR = 2.33, 95% CI = 1.60 to 3.39), and all adenocarcinoma 
for men (summary OR = 2.13, 95% CI = 1.86 to 2.44) and women 
(summary OR = 1.95, 95% CI = 1.40 to 2.71) (Supplementary 
Tables 1 and 2, available online). The slight differences in the 
summary odds ratios between men and women were not statisti-
cally significant (data not shown). Sex-specific analyses also showed 
statistically significant dose–response relationships in all adenocar-
cinoma, akin to summary odds ratios estimated from the sexes 
combined. This is explicitly emphasized by the summary odds 
ratios for the cigarette smoking pack-year categories of less than 15 
pack-years (men: summary OR = 1.33, 95% CI = 1.06 to 1.68; 
women: summary OR = 1.33, 95% CI = 0.97 to 1.83), 15–29 pack-
years (men: summary OR = 2.26, 95% CI = 1.88 to 2.73; women: 
summary OR = 2.03, 95% CI = 1.25 to 3.31), 30–44 pack-years 
(men: summary OR = 2.37, 95% CI = 1.97 to 2.85; women: summary 
OR = 2.24, 95% CI = 1.35 to 3.72), and greater than or equal to 45 
pack-years (men: summary OR = 2.67, 95% CI = 2.15 to 3.32; 
women: summary OR = 3.59, 95% CI = 2.30 to 5.60), respectively 
(Supplementary Tables 1 and 2, available online).
Next, we examined if gastroesophageal reflux and BMI modified 
the relationship between cigarette smoking and adenocarcinoma 
risk. Adjusting for gastroesophageal reflux in the multivariable 
logistic regression models of the five studies that had gastroesoph-
ageal reflux data (11,12,14,17,18) had minimal effect on the study-
specific and pooled summary odds ratios (data not shown). 
However, reflux was retained in these models as it is known to be 
a strong risk factor for esophageal adenocarcinoma and esopha-
gogastric junctional adenocarcinoma (27,28). We also found no 
evidence to suggest that BMI modified the association between 
cigarette smoking and adenocarcinoma risk. Analyses stratified by 
a BMI value of 25 produced similar estimates of risk for adenocar-
cinoma, and a meta-analysis of the interaction term BMI multi-
plied by pack-years of cigarette smoking was also indicative of no 
statistical interaction (P = .73) (data not shown). In addition, impu-
tation of age of smoking initiation in NIH-AARP by multivariable 
regression of age, sex, and BMI had minimal effect on risk esti-
mates ascertained compared with those derived using the me-
dian age 17 (data not shown), so the latter method was retained for 
clarity. Sensitivity analyses were conducted for all pack-year 
analyses and it was visually apparent that no single study substan-
tially dominated the values of the summary odds ratios (data not 
shown).
Finally, we examined the association of smoking intensity (packs 
per day), age of smoking initiation (<17 or ≥17 years), cigarette type 
(filtered, nonfiltered, or both), and duration of cigarette smoking 














   
 <1 986 471 1.00 (referent)
 1 654 461 1.04 (0.79 to 1.38) 27
 >1 842 675 0.92 (0.63 to 1.32) 38
Age of smoking  
    initiation,§ y
   
 <17 1047 814 1.00 (referent)
 ≥17 1475 830 1.02 (0.86 to 1.21) 11
Cigarette type║    
 Filtered only 457 295 1.00 (referent)
 Nonfiltered  
  only
335 249 1.40 (0.86 to 2.28) 59




   
 0 1106 707 1.00 (referent)
 <10 769 357 0.82 (0.60 to 1.13) 56
 ≥10 2091 920 0.71 (0.56 to 0.89) 39
* Results were adjusted for pack-years of smoking (categorical: <15, 15–29.9, 
30–44.9, ≥45), age (categorical: <50, 50–59, 60–69, ≥70), body mass index 
(categorical: <25, 25–29.9, ≥30), sex, education (study specific), and reflux 
(when available). Summary odds ratios and 95% confidence intervals were 
obtained from random-effects meta-analytic models. Age of smoking initi-
ation and duration of cessation were dichotomized based on their median 
values among control subjects, 17 and 10 years, respectively. Studies were 
only included in an analysis if they were able to provide exposure variables 
and sufficient numbers of case patients and control subjects for generation 
of stable risk estimates.
† I2 Percentage of total variation across studies because of heterogeneity.
‡ Nine BEACON studies were included in the analysis (9–12,14–18).
§ Ten BEACON studies were included in the analysis (9–18).
║ Five BEACON studies were included in the analysis (9–12,14).
¶ Eleven BEACON studies were included in the analysis (9–19).
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adenocarcinoma, esophagogastric junctional adenocarcinoma, and 
all adenocarcinoma. In addition, our results demonstrate that risk 
increases monotonically with increasing total dose (pack-years). 
Last, they show a risk reduction after smoking cessation, compared 
with current smokers.
In total, these results provide strong support for an association 
between cigarette smoking and adenocarcinomas of the esophagus 
and esophagogastric junction. Tobacco smoke is known to contain 
several carcinogens (29), which provides mechanistic support to 
our conclusions. In addition, the temporal relationships of these 
exposures and outcomes also provide supporting evidence; ciga-
rette smoking is typically initiated many years before tumor diag-
nosis in smokers. Plausible biological mechanisms that may explain 
the association between cigarette smoking and adenocarcinoma, 
either singly or in combination, include the genotoxicity of tobacco 
smoke to esophageal cells (30), increased gastroesophageal reflux 
via induced transient lower esophageal sphincter relaxations 
from biologically active constituents of tobacco smoke (31,32), 
and changing constituents of cigarettes over time with in-
creasing amounts of nitrosamines (33).
Summary odds ratios for analyses of cigarette smoking, shown 
herein, were similar for esophageal adenocarcinoma and esopha-
gogastric junctional adenocarcinoma, although these cancers have 
other features in common, too. They are both more common 
among white men (21) and share several risk factors including 
obesity (34,35) and gastroesophageal reflux (36). Similarity of risk 
factors could, in part, be due to the fact that these two tumor 
types cannot always be accurately distinguished from one another. 
Occasionally, tumors may traverse the esophagogastric junction, 
which can make the site of origin diagnostically contentious. 
Although traversing cancers may lead to misclassification, the 
above similarities between esophageal adenocarcinoma and esoph-
agogastric junctional adenocarcinoma, and the fact that all studies 
included in analyses of this pooling project present fairly homoge-
neous estimates of risk, should assuage concerns that these results 
are significantly altered via misclassification bias. Given the simi-
larities between esophageal adenocarcinoma and esophagogastric 
junctional adenocarcinoma, we decided to combine these cancers 
into one analytic category—that of all adenocarcinoma.
Prospective studies (37) have shown that smoking also increases 
the risk of gastric noncardia adenocarcinoma by approximately 
twofold (hazard ratio = 2.04, 95% CI = 1.32 to 3.16) (19). Therefore, 
one may conclude that cigarette smoking increases the risk of all 
adenocarcinomas of the esophagus and stomach by an average of 
twofold, and that risk increases further with increasing total 
dose (pack-years of cigarette smoking). In comparison, smoking is 
a stronger risk factor for squamous cell carcinoma of the esophagus 
(10,11,19,38), the other major histological type of esophageal 
cancer.
Our pooled analysis, to our knowledge, provides the first 
precise sex-specific risk estimates of the associations between 
cigarette smoking and esophageal adenocarcinoma and esopha-
gogastric junctional adenocarcinoma. Summary odds ratios of these 
associations were similar for men and women. These results are 
consistent with previous studies of lung cancer showing that the 
association with cigarette smoking is similar in both sexes (39,40). 
Estimating the proportions of esophageal adenocarcinoma or 
esophagogastric junctional adenocarcinoma that are associated 
with cigarette smoking is difficult because cigarette smoking prev-
alence varies by population and has changed over time, and the exact 
time period between exposures and outcome, which is etiologically 
relevant, is unclear. Because men have traditionally smoked more 
than women (41), cigarette smoking has likely caused many more 
adenocarcinomas of the esophagus and esophagogastric junction in 
men than in women, which may account for part of the sex differences 
in the incidence of these cancers. However, because the prevalence of 
smoking in the United States has been declining and converging 
between the sexes since 1965 (41), it is unlikely that smoking could 
explain the recent and continuing rise of esophageal adenocarcinoma 
(42) and the eightfold difference in sex disparity (23).
Cigarette smoking is one of the most extensively investigated 
exposures in epidemiological studies, and several models have been 
used for analysis of smoking in relation to health outcomes (43,44). 
In lung cancer studies, it has been argued that the contribution of 
smoking intensity and duration to risk of disease may not be equal, 
and therefore, using cumulative total exposure in terms of pack-
years may not be an optimal strategy to deduce risk associations 
(43). Other authors have suggested using duration and intensity as 
separate variables in analytic models, but for a constant duration, 
increasing intensity means increased total exposure, so attributing 
the effect to intensity could be misleading (45,46). Therefore, as 
Samet et al. (41) noted, there is perhaps no single model that is 
entirely satisfactory. We chose categories of pack-years of cigarette 
smoking as the main exposure because of the following reasons: 
most studies have shown a dose–response association of this vari-
able with lung and other cancers (47); interpretation of the results 
is relatively easy; results are meaningful for causal inferences and 
public health purposes; and no assumptions are made about line-
arity of the associations.
Because of the fact that total exposure is affected by smoking 
intensity, smoking duration, age of smoking initiation, and years of 
smoking cessation, we adjusted for total exposure (pack-years) 
when analyzing these associations. After adjustment, we did not 
observe any association between smoking intensity, age of smoking 
initiation, and cigarette type, with risk of esophageal adenocarci-
noma or esophagogastric junctional adenocarcinoma. Because total 
exposure is the product of intensity and duration, no effect of 
intensity after adjustment for total exposure suggests that for a 
constant total exposure, lower intensity and longer duration have 
approximately the same effect as higher intensity and shorter 
duration. More in-depth analyses, including wasted dose, which is 
defined as reduced carcinogenic potency of higher smoking intensities 
relative to lower intensities given equal total exposure (45,46,48,49), 
may reveal more details.
We noted that cigarette type was not statistically significantly 
associated with risk of esophageal adenocarcinoma or esophago-
gastric junctional adenocarcinoma after taking into consideration 
total exposure. Data on the effect of cigarette type on these cancers 
are sparse. However, for lung cancer, the body of evidence accu-
mulated so far suggests that both filtered and nonfiltered cigarettes 
substantially increase the risk of cancer (50). Also, studies show 
that there is little difference, if any, between cigarette types in their 
carcinogenic potential or in the amount of tar or nicotine that 
smokers receive from them (50).
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Because there was a dose–response relationship with pack-years 
in our analyses, we speculated that smoking cessation might 
truncate further increase in risk. Our analyses showed that even 
after adjusting for total pack-years, smoking cessation was associ-
ated with risk reduction. In other words, if one quits smoking 
today, one’s risk would not only stop increasing but may also 
decrease over time. However, the summary odds ratios for greater 
than or equal to 10 years of smoking cessation suggested that risk 
does not decrease to the level of never–cigarette smokers. Indeed, 
the risk of all adenocarcinoma in those with greater than or equal 
to 10 years of smoking cessation was 1.7-fold of that of never–
cigarette smokers (data not shown). Still, little is known about the 
long-term effects of smoking cessation on risk of all adenocarci-
noma after adjusting for pack-years, and even this analysis had only 
adequate statistical power to stratify the sample into three groups 
of exposure. Using lung cancer as a model, most long-term studies 
with follow-up of up to 40 years have shown that although further 
increased risk of lung cancer is avoided by quitting, the risk will 
always remain higher in cigarette smokers than in never–cigarette 
smokers (50).
Although our results demonstrate clear relationships of ciga-
rette smoking with esophageal adenocarcinoma and esophagogas-
tric junctional adenocarcinoma, it is unlikely that smoking is solely 
responsible for the recent increase in cancer incidence. The prev-
alence of cigarette smoking started rising from 1881 (51) when 
James Bonsack invented the first cigarette-rolling machine; yet, 
incidence of esophageal adenocarcinoma was still very low 95 years 
later, in the mid-1970s (42). Prevalence of smoking among the 
United States male population started declining from 1965 (52) 
after publication of the first report of the United States Surgeon 
General on smoking and health (53); yet, esophageal adenocarci-
noma rates, especially among white men, are still increasing (42). 
During the same period that esophageal adenocarcinoma and 
esophagogastric junctional adenocarcinoma rates have increased, 
incidence rates of esophageal squamous cell carcinoma, a cancer 
closely related to smoking, have decreased (42). Although a longer 
latency period for esophageal adenocarcinoma may account for 
part of the difference between esophageal adenocarcinoma and 
esophageal squamous cell carcinoma, it is unlikely to explain it all. 
Furthermore, because cigarette smoking on average increases 
esophageal adenocarcinoma risk by twofold and only a fraction of 
the population smoke, cigarette smoking can at most contribute 
only part of the recent four- or fivefold increased incidence 
observed in some populations (42).
This combined analysis has several notable strengths, including 
its large sample size, inclusion of population-based case–control 
and cohort studies, and availability of data on major confounders. 
The use of individual-level data permitted combined analyses with 
comparable variables, a feature not available in meta-analyses that 
use only published odds or risk ratios. There was no evidence of 
substantial heterogeneity between the study populations; results 
were robust to the choice of analytic methods (adjustment for 
confounders and random- vs fixed-effect models), analytic sub-
groups (men vs women and tumor location), and study design 
(case–control vs cohort).
This analysis may have several limitations. Because it is difficult 
to differentiate esophageal adenocarcinoma from esophagogastric 
junctional adenocarcinoma and adenocarcinomas of the lower 
stomach, there may have been misclassification. However, this 
misclassification may be less of a problem in this analysis, given the 
consistency of association across sites, and therefore, we decided to 
produce a combined analytic group pertaining to these sites—all 
adenocarcinoma. Also, case–control studies may be affected by 
recall bias and interviewer bias, although the intensity and dura-
tion of smoking are usually recalled relatively reliably (54), but the 
two cohort studies (which obtained exposure information before 
the outcome) included in our pooled analysis showed results similar 
to those of the case–control studies. Therefore, we believe these 
biases are unlikely to have had a major impact on the results.
In summary, we found a statistically significant dose–response 
association between cigarette smoking and adenocarcinomas of the 
esophagus and esophagogastric junction that was seen in both men 
and women. Smoking cessation reduced the risk with decreasing 
risk associated with longer duration since quitting. These results 
strongly suggest that cigarette smoking is causally related to these 
two cancers.
Supplementary Data
Supplementary data can be found at http://www.jnci.oxfordjournals 
.org/.
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